GLP-1 Medication and Alcohol: Drinking, Cravings, and What the Research Shows

Alcohol can worsen nausea while taking a GLP-1 and may increase low-blood-sugar risk for people with diabetes who also use other glucose-lowering medicines⁵. Ask your prescriber how that applies to you. Research into semaglutide for alcohol use disorder is encouraging, but the 2025 trial discussed here was small and improved some drinking measures, not all of them¹.

"Can you drink on Ozempic?" is a common question, but the more interesting story is the other direction: a real and growing body of clinical evidence suggests GLP-1 medications may reduce alcohol consumption and cravings, enough that they're now being formally tested as an alcohol use disorder treatment. Here's the practical guidance and the emerging science behind it.

Discuss drinking with your prescriber

The absence of a blanket alcohol prohibition is not a guarantee that drinking is safe for you. Alcohol and GLP-1 medications can both cause nausea and affect blood sugar. Combining them may worsen stomach symptoms and, for people with diabetes using other glucose-lowering medicines, increase the risk of low blood sugar⁵. Alcohol also adds calories. Tell your prescriber how much you drink and which medicines you take, especially insulin or a sulfonylurea, so the advice reflects your situation rather than a general rule about moderation.

The more interesting finding: these drugs may reduce drinking

A 2025 phase 2 trial in JAMA Psychiatry randomized 48 adults with alcohol use disorder who were not seeking treatment to semaglutide or placebo for nine weeks. Semaglutide reduced alcohol consumed in a laboratory session, drinks per drinking day and weekly craving. It did not significantly change average drinks per calendar day or the number of drinking days¹. The study provides preliminary evidence for some outcomes, rather than proof that semaglutide treats alcohol use disorder across patient groups.

A large 2024 observational study in Nature Communications found lower incidence and recurrence of alcohol use disorder diagnoses among people prescribed semaglutide than among comparison patients². An association in medical records cannot by itself establish that the medicine caused the difference. The studies address different questions and should not be treated as interchangeable evidence.

Why this might be happening

Researchers have a plausible mechanism, not just a correlation. A 2023 study in JCI Insight found that semaglutide reduced alcohol drinking in preclinical models and appeared to modulate GABA neurotransmission in the brain — the same signaling system implicated in alcohol's rewarding effects³. This isn't entirely new territory for the drug class: an earlier randomized, placebo-controlled trial of exenatide (an older GLP-1 medication) in people with alcohol use disorder, published in 2022, had already hinted at a similar effect in a subgroup of patients⁴. The working theory is that GLP-1 receptor agonists act on reward-and-craving circuitry in the brain broadly, not just on appetite for food — which would explain why the effect shows up for alcohol specifically rather than just being an indirect result of feeling less hungry or less hungry-and-thirsty in general.

What this does and doesn't mean for you

This is not yet an FDA-approved use — none of the four approved GLP-1 brands are indicated for alcohol use disorder, and this section describes an active area of research, not a settled treatment protocol. If you're taking a GLP-1 for weight management and happen to notice you're drinking less or craving alcohol less, that's consistent with what the research above describes, but it isn't something to self-manage as addiction treatment. If alcohol use is a significant concern for you, tell your prescriber directly — it's relevant medical history regardless of what you're hoping the GLP-1 does about it, and a good clinician should be able to discuss both the emerging evidence and whether a dedicated alcohol use disorder treatment is more appropriate for your situation. This is exactly the kind of nuance real clinician support should surface — see our guide to side effects and how to manage them for the more common physical interactions, and how to choose a GLP-1 provider for what real clinical oversight should look like versus a provider that just ships medication.

If drinking or cravings concern you, bring them up during a clinical visit. The studies above support further research; they do not establish a drinking limit that is safe for everyone or replace an individual alcohol-use treatment plan.